INT4649

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 1976
Last Reported 2010
Negated 1
Speculated 1
Reported most in Abstract
Documents 17
Total Number 18
Disease Relevance 5.48
Pain Relevance 3.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Chrna7) plasma membrane (Chrna7) cytoplasm (Chrna7)
Anatomy Link Frequency
neuronal 1
smooth muscles 1
retina 1
muscles 1
chromaffin cells 1
Chrna7 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Pain 45 100.00 Very High Very High Very High
Inflammation 8 100.00 Very High Very High Very High
Potency 4 99.92 Very High Very High Very High
Botox 72 99.88 Very High Very High Very High
agonist 15 99.48 Very High Very High Very High
Freund adjuvant 2 98.32 Very High Very High Very High
tetrodotoxin 11 98.10 Very High Very High Very High
Piles 69 97.96 Very High Very High Very High
antagonist 14 97.96 Very High Very High Very High
Hyperalgesia 2 96.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Overactive Bladder 77 100.00 Very High Very High Very High
Cervical Cancer 5 99.90 Very High Very High Very High
Disease 18 99.24 Very High Very High Very High
Anorectal Disorders 75 97.96 Very High Very High Very High
Hyperalgesia 2 96.92 Very High Very High Very High
Recurrence 34 95.44 Very High Very High Very High
Wrinkles 26 95.24 Very High Very High Very High
Wound Healing 2 94.00 High High
Paralysis 20 93.20 High High
Clostridium Infection 7 90.00 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Altogether, given their high Ca(2+)-permeability, our results suggest a possible role of alpha7-nAChR on interneurons for activating Ca(2+)-dependent signaling in the vicinity of GABAergic and glutamatergic synapses.
Spec (possible) Positive_regulation (role) of alpha7-nAChR in interneurons associated with gabaergic
1) Confidence 0.50 Published 2010 Journal PLoS ONE Section Abstract Doc Link 20634896 Disease Relevance 0 Pain Relevance 0.34
Tetrodotoxin (2.0 x 10(-7) M) antagonized the effects of BTX, a finding which suggests that the actions of BTX are mediated by a selective increase in membrane permeability to sodium ions.
Positive_regulation (mediated) of BTX associated with tetrodotoxin
2) Confidence 0.50 Published 1976 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 1255486 Disease Relevance 0 Pain Relevance 0.14
The best characterized toxins are botulinum toxin type A (BTXA) and botulinum toxin type B (BTXB), both used therapeutically and commercially available.[12]

BTX: THE MOLECULAR MODE OF ACTION [FIGURE 1]

Positive_regulation (botulinum toxin type B) of BTX associated with botox
3) Confidence 0.49 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840887 Disease Relevance 0.27 Pain Relevance 0.24
Botulinum toxin (BTX) can be used for temporary chemical denervation to treat this painful disorder.
Positive_regulation (used) of BTX associated with pain
4) Confidence 0.46 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Abstract Doc Link PMC2840903 Disease Relevance 0.33 Pain Relevance 0.15
BTX action on hyperactive smooth muscles such as the anal sphincter is mediated by its action on the autonomic nervous system (as in striated muscles).
Positive_regulation (mediated) of BTX in smooth muscles
5) Confidence 0.46 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Body Doc Link PMC2840903 Disease Relevance 1.12 Pain Relevance 0.46
The specific binding of [3H]BTX-OAB was increased by the addition of Leiurus quinquestriatus quinquestriatus scorpion venom (ScTx) and inhibited by veratridine, a member of the same class of sodium channel activators.
Positive_regulation (increased) of BTX-OAB associated with sodium channel and overactive bladder
6) Confidence 0.40 Published 1993 Journal Toxicon Section Abstract Doc Link 8266344 Disease Relevance 0.51 Pain Relevance 0.36
With increasing evidence for its efficacy, BTX can now be considered among the first-line nonsurgical treatements.
Positive_regulation (increasing) of BTX
7) Confidence 0.38 Published 2008 Journal Journal of Cutaneous and Aesthetic Surgery Section Abstract Doc Link PMC2840903 Disease Relevance 0.40 Pain Relevance 0.11
Activation of the alpha7-nicotinic acetylcholine receptor reverses complete freund adjuvant-induced mechanical hyperalgesia in the rat via a central site of action.
Positive_regulation (Activation) of alpha7-nicotinic associated with hyperalgesia, inflammation and freund adjuvant
8) Confidence 0.30 Published 2008 Journal J Pain Section Title Doc Link 18420461 Disease Relevance 0.18 Pain Relevance 1.00
The potency of BTX for stimulation of sodium influx was increased (EC50 24 nM) in the presence of 0.6 microgram/ml scorpion venom without any change in maximal influx.
Positive_regulation (increased) of BTX associated with potency
9) Confidence 0.28 Published 1990 Journal Brain Res. Section Abstract Doc Link 1697206 Disease Relevance 0 Pain Relevance 0.42
Currently, the best treatment option for idiopathic cervical dystonia (ICD) is injection of botulinum toxin (BTX) into the affected muscles, whereas rehabilitative approaches have given disappointing results.
Positive_regulation (injection) of BTX in muscles associated with cervical cancer
10) Confidence 0.23 Published 2006 Journal Mov. Disord. Section Abstract Doc Link 17029278 Disease Relevance 0.35 Pain Relevance 0
The mean diaphragmatic elevation in BTX-A and control groups were 7.0 ± 2.5 and 1.3 ± 1.2 millimetres respectively.
Positive_regulation (elevation) of BTX
11) Confidence 0.22 Published 2005 Journal Int Semin Surg Oncol Section Abstract Doc Link PMC1266393 Disease Relevance 0.14 Pain Relevance 0.08
We detected significant diaphragmatic elevation in the BTX-A group at day 7.
Positive_regulation (elevation) of BTX
12) Confidence 0.22 Published 2005 Journal Int Semin Surg Oncol Section Body Doc Link PMC1266393 Disease Relevance 0.54 Pain Relevance 0.09
BTX is not approved for the treatment of OAB but is now widely used in patients who are refractory to conventional antimuscarinic therapy or who do not tolerate it due to systemic side effects.
Neg (not) Positive_regulation (approved) of BTX associated with overactive bladder
13) Confidence 0.04 Published 2010 Journal F1000 Med Rep Section Body Doc Link PMC2948402 Disease Relevance 0.68 Pain Relevance 0.04
Eighty-four percent of these patients received a reinjection of BTX-A on average five months after the first treatment.
Positive_regulation (reinjection) of BTX
14) Confidence 0.03 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2946856 Disease Relevance 0.50 Pain Relevance 0
The products have different amounts of complexing proteins or are free of complexing proteins (ie, Xeomin®/Bocouture®).6 The diffusion of the different drugs seems to be dependent on concentration.7 BTX-A has an excellent safety profile8 and has been used extensively for facial rejuvenation with a focus on hyperkinetic wrinkles and to improve facial wound healing after surgery.9–12

Fillers

Positive_regulation (dependent) of BTX associated with wrinkles and wound healing
15) Confidence 0.03 Published 2010 Journal Clin Interv Aging Section Body Doc Link PMC2946856 Disease Relevance 0.46 Pain Relevance 0.04
Electrophysiological and biochemical techniques were used to demonstrate that alpha-bungarotoxin-, methyllycaconitine-sensitive neuronal nicotinic acetylcholine receptors (nAChRs) can be activated via a novel agonist site(s).
Positive_regulation (activated) of alpha-bungarotoxin in neuronal associated with agonist
16) Confidence 0.02 Published 1993 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8510023 Disease Relevance 0 Pain Relevance 0.19
Regulation of alpha-bungarotoxin receptor accumulation in chick retina cultures: effects of membrane depolarization, cyclic nucleotide derivatives, and Ca2+.
Positive_regulation (accumulation) of alpha-bungarotoxin receptor in retina
17) Confidence 0.02 Published 1983 Journal J. Neurosci. Section Title Doc Link 6306174 Disease Relevance 0 Pain Relevance 0.11
Marked up-regulation of the beta-bungarotoxin site in adrenal chromaffin cells by specific nicotinic antagonists.
Positive_regulation (up-regulation) of beta-bungarotoxin site in chromaffin cells associated with antagonist
18) Confidence 0.00 Published 1987 Journal Mol. Pharmacol. Section Title Doc Link 3574287 Disease Relevance 0 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox